Search Results - "Kiefer, Gauri"

Predictors and Consequences of Cancer and Non-Cancer-Related Pain in Those Diagnosed with Primary and Metastatic Cancers by Shah, Kriti, Geller, David A, Tohme, Samer, Antoni, Michael, Kallem, Cramer J, Vodovotz, Yoram, Ramanathan, Rekha, Naveen, Raam, Geroni, MacKenzie, Devine, LaNita, Amin, Aarshati, Kiefer, Gauri J, Zandberg, Dan P, Reyes, Vincent, Steel, Jennifer L

“…The aims of the study were to (1) describe types of pain in cancer patients, (2) examine the predictors and consequences of pain, (3) investigate the…”
Get full text

SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study) by Borghaei, Hossein, Redman, Mary W., Kelly, Karen, Waqar, Saima N., Robert, Francisco, Kiefer, Gauri J., Stella, Philip J., Minichiello, Katherine, Gandara, David R., Herbst, Roy S., Papadimitrakopoulou, Vassiliki A.

“…The objective of the Lung-MAP sub-study S1400A was to evaluate the response rate to durvalumab, an anti-programmed death-ligand 1 (PD-L1) antibody, in patients…”
Get full text

Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer by Brell, Joanna M, Matin, Khalid, Evans, Terry, Volkin, Robert L, Kiefer, Gauri J, Schlesselman, James J, Dranko, Shelley, Rath, Linda, Schmotzer, Amy, Lenzner, Diana, Ramanathan, Ramesh K

“…There is no standard second-line therapy for advanced pancreatic cancer (APC). We evaluated the epidermal growth factor receptor (EGFR) inhibitor gefitinib and…”
Get more information

Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial by Steel, Jennifer L, George, Charles J, Terhorst, Lauren, Yabes, Jonathan G, Reyes, Vincent, Zandberg, Dan P, Nilsen, Marci, Kiefer, Gauri, Johnson, Jonas, Marsh, Christopher, Bierenbaum, Jason, Tageja, Nishant, Krauze, Michal, VanderWeele, Robert, Goel, Gaurav, Ramineni, Gopala, Antoni, Michael, Vodovotz, Yoram, Walker, Jon, Tohme, Samer, Billiar, Timothy, Geller, David A

“…The current standard of care of screening and referring patients for treatment for symptoms, such as depression, pain, and fatigue, is not effective. This…”
Get full text

A phase III randomized controlled trial of a stepped collaborative care intervention versus standard of care by Steel, Jennifer Lynne, Reyes, Vincent Edgar, Terhorst, Lauren, George, Charles Joseph, Johnson, Jonas T., Krauze, Michael, Bierenbaum, Jason, Tageja, Nishant, Kiefer, Gauri J., Nilsen, Marci Lee, Goel, Gaurav, VanderWeele, Robert Alan, Marsh, Christopher Ritchie, Ramineni, Gopala Amarnath, Zandberg, Dan Paul, Antoni, Michael, Tohme, Samer, Geller, David A.

“…e24191 Background: The aims of this study were to screen patients for symptoms of depression, pain, and/or fatigue and test the efficacy of a stepped…”
Get full text

Stress as a predictor of tumor growth and development of metastases by Peyser, Tristen, Geller, David A., Terhorst, Lauren, Antoni, Michael, Vodovotz, Yoram, Hausmann, Leslie, Olejniczak, Donna, Amin, Aarshati, Kiefer, Gauri J., Hecht, Carol Lynn, Miceli, Jessica, Tong, Albert, Johnson, Jonas T., Nilsen, Marci Lee, Zandberg, Dan Paul, Reyes, Vincent Edgar, Steel, Jennifer

“…Abstract only e24124 Background: The aims of this study were to examine; the predictors of perceived stress; and the associations between perceived stress and…”
Get full text

The benefits and consequences of the COVID‐19 pandemic for patients diagnosed with cancer and their family caregivers by Steel, Jennifer L., Amin, Aarshati, Peyser, Tristen, Olejniczak, Donna, Antoni, Michael, Carney, Maureen, Tillman, Emily, Hecht, Carol Lynn, Pandya, Niva, Miceli, Jessica, Reyes, Vincent, Nilsen, Marci, Johnson, Jonas, Kiefer, Gauri, Pappu, Bhanu, Zandberg, Dan P., Geller, David A.

“…Background The objectives of this study were to examine benefits and consequences of the COVID‐19 pandemic for patients diagnosed with cancer and their family…”
Get full text

Overcoming clinical trial accrual barriers at UPMC: A successful experience by Reyes, Vincent Edgar, Evans, Terry L., VanderWeele, Robert Alan, Marsh, Christopher Ritchie, Peracha, Sajid M., Kiefer, Gauri J., Tageja, Nishant, Choksi, Rushir J., Pappu, Bhanu, Wozniak, Antoinette J., Ferris, Robert L., Marks, Stanley M.

“…Abstract only e14152 Background: UPMC Hillman Cancer Center Medical Oncology Network is one of the largest integrated community oncology network in the United…”
Get full text

The next generation of collaborative care: The design of a novel web-based stepped collaborative care intervention delivered via telemedicine for people diagnosed with cancer by Steel, Jennifer L., Reyes, Vincent, Zandberg, Dan P., Nilsen, Marci, Terhorst, Lauren, Richards, Geena, Pappu, Bhanu, Kiefer, Gauri, Johnson, Jonas, Antoni, Michael, Vodovotz, Yoram, Spring, Michael, Walker, Jon, Geller, David A.

“…The NIH consensus statement on cancer-related symptoms concluded the most common and debilitating were depression, pain and fatigue [1–6]. Although the…”
Get full text

Trait mindfulness and the mental and physical health of caregivers for individuals with cancer by Hecht, Carol Lynn, Amin, Arshati, Miceli, Jessica, Olejniczak, Donna, Peyser, Tristen, Geller, David A., Antoni, Michael, Kiefer, Gauri, Reyes, Vincent, Zandberg, Dan P., Johnson, Jonas T., Nilsen, Marci L., Tohme, Samer, Steel, Jennifer L.

“…Mindfulness plays a role in one's mental and physical health outcomes. The aims of this study were to examine the relationship between trait mindfulness and…”
Get full text

A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas by Lo, Shelly S, Khorana, Alok A, Javle, Milind, Simon, Sheryl, Kiefer, Gauri, Rajasenan, Kiran, Wang, Hong, Hantel, Alexander, Shayne, Michelle, Hwang, Jimmy, Schmotzer, Amy, Ramanathan, Ramesh K

“…Docetaxel and capecitabine are active agents in advanced gastric and gastroesophageal (GE) carcinomas. This multi-institutional phase II trial evaluates the…”
Get more information

Early Clinical and Pharmacokinetic Results of Lower Dose Fludarabine and Cyclophosphamide, and High Dose Rituximab (FCR-Lite) for Patients with Untreated Chronic Lymphocytic Leukemia (CLL) by Tarhini, Ahmad A., Land, S., Meisner, D., Pietragallo, L., Sulecki, M., Lim, F., Kiefer, Gauri J., Pinkerton, R., Obsorn, J., Sukaly, S., Schaefer, P.M., Foon, Kenneth A.

“…Introduction Standard FCR therapy in untreated CLL patients (F-25 mg/m2 d1–3 q 4wk; C-250 mg/m2 d 1–3 q 4wk; R-500 mg/m2 d1 q 4wk for 6 cycles) was recently…”
Get full text

Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy by Patel, Hitendra, Stoller, Ronald, Auber, Miklos, Potter, Douglas, Cai, Chao, Zamboni, William, Kiefer, Gauri, Matin, Khalid, Schmotzer, Amy, Ramanathan, Ramesh K

“…Rubitecan (RFS-2000, 9NC, Orathecin) is an orally bioavailable camptothecin analogue, with evidence of preclinical activity in colon cancer cell lines. We…”
Get full text